GO
View AllPharmaBiotechMedical
Devices
Health
Care
Animal
Health
5 April 2018
We have our transition period for goods but what about the regulations? How the life sciences industry may be affected by Brexit

The European Commission published a Draft Withdrawal Agreement (the Agreement) on 19 March 2018. The Agreement...

7 March 2018
Side CAR-Ts

Big pharma’s interest in chimeric antigen receptor (CAR)-T therapies is clear:  companies such as Novartis...

20 February 2018
CAR-T rolls on

Over recent months, the cellular immunotherapy landscape has continued to develop apace.  Various new acquisitions...

16 February 2018
The competition law issues of the CRISPR patent pool

CRISPR-Cas9 is heralded as a revolutionary gene editing technology that is regularly hitting the headlines...

16 February 2018
Different types of value transfer in ‘reverse payment’ settlement agreements

In recent years, competition authorities and courts in the EU and the US have paid...

9 February 2018
Specific Mechanism applies to extended SPC period opines AG Tanchev

On 7 February 2018 Advocate General Tanchev delivered his opinion in Pfizer Ireland Pharmaceuticals v...

9 February 2018
AG Opinion: Organisms obtained by mutagenesis are GMOs exempt from the provisions of the GMO Directive

Advocate General Bobek’s opinion in a reference from the Conseil d’État to the CJEU[1] for a...

6 February 2018
Proposal to extend UK withholding tax on royalties - The start of a major shift in the UK’s approach to taxation?

The UK Government has today announced a Life Sciences Sector Deal as part of its new Industrial Strategy. The...

29 January 2018
10 key points on Parallel Trade and Pharma

Parallel trade is the cross-border sale of goods within the EU by traders outside of...

24 January 2018
Evolving how English courts construe written commercial contracts (Teva v AstraZeneca)

Teva v AstraZeneca [2017] EWCA Civ 2135 is the latest case in a line of cases...

24 January 2018
Misleading information and competition law - Case C-179/16 CJEU Judgment of 23 January 2018 (Avastin/Lucentis –Italy)

This case relates to the interplay between EU competition law and the pharmaceutical regulatory regime....

17 January 2018
Impact of Brexit on International Data Transfer Mechanisms

Currently in relation to personal data, and particularly health data, there are a number of...

12345678>>>